2010 Fiscal Year Final Research Report
Genetic polymorphisms to analyze and predict treatment-related adverse effects in children with acute lymphoblastic leukemia
| Project/Area Number |
20790135
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
NAKAMURA Tsutomu Kobe University, 薬学部, 教授 (80379411)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | オーダーメード医療 |
|---|
| Research Abstract |
Some children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) experience clinically important treatment-related adverse effects. In the present study, to identify novel potential loci influencing the risk of treatment-related hepatotoxicity during the maintenance phase, a genome-wide genotyping analysis was performed in Japanese children with ALL or LBL. Genome-wide genotyping uncovered a total of 28 candidate SNPs. rs1966862, in Rho GTPase-activating protein 24 (ARHGAP24), was the most significant of the candidates, and the genotypes of rs7403531 (RASGRP1) and some genes were also significantly associated with severe hepatotoxicity. This study suggested rs1966862 (ARHGAP24) and the other SNPs to be predictive factors for drug-induced hepatotoxicity during the maintenance phase in pediatric patients with ALL or LBL.
|
